TW202334116A - 一種取代的苯丙酸衍生物及其用途 - Google Patents

一種取代的苯丙酸衍生物及其用途 Download PDF

Info

Publication number
TW202334116A
TW202334116A TW111142050A TW111142050A TW202334116A TW 202334116 A TW202334116 A TW 202334116A TW 111142050 A TW111142050 A TW 111142050A TW 111142050 A TW111142050 A TW 111142050A TW 202334116 A TW202334116 A TW 202334116A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
independently selected
alkyl
Prior art date
Application number
TW111142050A
Other languages
English (en)
Chinese (zh)
Inventor
譚亮
董玉瓊
劉敏
李姣
健 李
張瑱
林曉燕
李云飛
Original Assignee
大陸商上海拓界生物醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海拓界生物醫藥科技有限公司 filed Critical 大陸商上海拓界生物醫藥科技有限公司
Publication of TW202334116A publication Critical patent/TW202334116A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111142050A 2021-11-03 2022-11-03 一種取代的苯丙酸衍生物及其用途 TW202334116A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202111293711.9 2021-11-03
CN202111293711 2021-11-03
CN202211033065 2022-08-26
CN202211033065.7 2022-08-26

Publications (1)

Publication Number Publication Date
TW202334116A true TW202334116A (zh) 2023-09-01

Family

ID=86240694

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142050A TW202334116A (zh) 2021-11-03 2022-11-03 一種取代的苯丙酸衍生物及其用途

Country Status (10)

Country Link
US (1) US20250042847A1 (cg-RX-API-DMAC7.html)
EP (1) EP4428129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540183A (cg-RX-API-DMAC7.html)
KR (1) KR20240091010A (cg-RX-API-DMAC7.html)
CN (1) CN118055927A (cg-RX-API-DMAC7.html)
AU (1) AU2022381258A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235992A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005304A (cg-RX-API-DMAC7.html)
TW (1) TW202334116A (cg-RX-API-DMAC7.html)
WO (1) WO2023078333A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217537A1 (zh) * 2023-04-21 2024-10-24 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
TW202444710A (zh) * 2023-05-11 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 一種脂蛋白化合物晶型及其製備方法
KR20260041098A (ko) * 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
CN121548567A (zh) * 2023-07-21 2026-02-17 伊莱利利公司 具有Lp(a)降低活性的哌啶、吗啉和四氢哒嗪化合物
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
CN122535600A (zh) * 2023-11-17 2026-08-07 上海翊石医药科技有限公司 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途
CN122270439A (zh) * 2023-11-20 2026-06-23 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025199298A1 (en) 2024-03-21 2025-09-25 Eli Lilly And Company BIOMARKER ASSAY TO MEASURE LIPOPROTEIN(a)
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
CN121627662A (zh) * 2024-09-05 2026-03-10 成都康弘药业集团股份有限公司 芳基丙酸化合物及其制备方法与用途
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
WO2026119122A1 (zh) * 2024-12-02 2026-06-11 上海喆邺生物科技有限公司 一种苯丙酸衍生物及其医药用途
WO2026130347A1 (zh) * 2024-12-17 2026-06-25 上海喆邺生物科技有限公司 一种吡咯烷衍生物及其在药物中的用途
WO2026130471A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 吡咯烷衍生物或其盐的制备方法
CN121609698B (zh) * 2026-01-30 2026-06-02 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1962596A (zh) * 2000-10-11 2007-05-16 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
MXPA03003021A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
AU2003300438A1 (en) * 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
US7705177B2 (en) * 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7919506B2 (en) * 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CA2708706A1 (en) * 2007-12-10 2009-06-18 7Tm Pharma A/S Cannabinoid receptor modulators
KR102720992B1 (ko) 2019-06-07 2024-10-24 일라이 릴리 앤드 캄파니 피롤리딘 화합물
EP4469435A1 (en) * 2022-01-26 2024-12-04 Eli Lilly and Company Pyrrolidine compounds

Also Published As

Publication number Publication date
EP4428129A1 (en) 2024-09-11
JP2024540183A (ja) 2024-10-31
WO2023078333A1 (zh) 2023-05-11
MX2024005304A (es) 2024-05-17
AU2022381258A1 (en) 2024-05-02
US20250042847A1 (en) 2025-02-06
CN118055927A (zh) 2024-05-17
EP4428129A4 (en) 2025-05-07
WO2023078333A8 (zh) 2023-08-10
KR20240091010A (ko) 2024-06-21
CA3235992A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
WO2023078333A1 (zh) 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途
US12240849B2 (en) Nitrogen-containing spiro derivative as RET inhibitor
WO2024067857A1 (zh) 大环衍生物及其应用
CN115884971A (zh) 取代的哌啶化合物及其用途
US20250115572A1 (en) Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
CN117940422A (zh) 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸,1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式
CN105209448A (zh) 三环化合物及其用途
US12428373B2 (en) Dopamine D2 receptor ligands
KR20250128379A (ko) 보체인자 b의 억제제
JP7030776B2 (ja) アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
CN116507613A (zh) 稳定转甲状腺蛋白四聚体的视黄醇结合蛋白4的双特异性拮抗剂及其制备和在治疗常见年龄相关合并症中的用途
US20240400571A1 (en) 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
TWI886832B (zh) 大環衍生物及其應用
US12152008B2 (en) Cyclopentaimidazolones for the treatment of cancer
HK40083601B (en) Substituted piperidine compound and application thereof
WO2025077867A1 (zh) 吡啶酮并环类衍生物及其应用
WO2026052060A1 (zh) 一类苯甲酰基甘氨酸衍生物及其制备方法和应用
KR20240144990A (ko) 시클로헥세논 화합물의 결정형
WO2025045777A1 (en) Inhibitors of pcsk9
CA3268322A1 (en) Macrocyclic derivative and use thereof
HK40122781A (en) Macrocyclic derivative and use thereof
WO2025223511A1 (zh) 一类苯甲酰基甘氨酸衍生物及其制备方法和应用
CN113801120A (zh) Mdm2抑制剂的微悬浮液以及治疗应用
BR112021019629B1 (pt) Composto de uma fórmula (ii) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do composto ou o sal farmaceuticamente aceitável do mesmo